722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II

A Prospective Randomized Clinical Trial Comparing a Calcineurin-Free Gvhd Prophylaxis Regimen with Post-Transplant Cyclophosphamide and Abatacept to M

Is the Youngest Donor Always the Best Choice to Optimize Outcomes for Matched Unrelated Allogeneic Transplant? Improving Precision Using Novel Statist

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

A Novel JAK1 Inhibitor SHR0302 for Treatment of Chronic Graft-Verse-Host Disease: A Phase I Clinical Trial

Post-Transplant Cyclophosphamide, Abatacept, and Vedolizumab to Prevent Graft-Versus-Host Disease after Hematopoietic Stem Cells Transplantation from

Real-World Outcomes of Pfts in Screening for Lung Involvement in Chronic Gvhd Post-Allogeneic Stem Cell Transplant: A Retrospective Study of 387 Patie

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy P

Development of a Stacked Ensemble Model for Risk Stratification of Chronic Gvhd after Allogeneic HSCT: Trump Cohort Study

Allogeneic Hematopoietic Cell Transplant Recipients Carrying DNMT3A and ASXL1 Mutations More Frequently Develop Severe Graft Versus Host Disease and A

Mesenchymal Stromal Cell Infusion Might Improve Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplantation and Modulate Alveola

Reconstitution Dynamics and Impact on Clinical Outcomes of Mucosal-Associated Invariant T-Cells in Pediatric Patients Receiving Allogeneic Hematopoiet

Combining Low-Dose Post-Transplant Cyclophosphamide(PTCY) with Anti-Thymocyte Globulin(ATG) for Prophylaxis of Graft-Versus-Host Disease in Alternativ

Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Chronic Steroid-Refractory Graft-Versus-Host Disease after Hematopoietic S

Early Prognostic Biomarkers of Non-Relapse Mortality in Allogeneic Mismatched Unrelated Hematopoietic Cell Transplantation

PB CD8 TN and CD4 TEM on day30 after Allo-HSCT Is a Predictive Marker for the Development of aGVHD

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Leves Are Significantly Associated with Ed

Dynamics of Immune Reconstitution after Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide Compared to Classical Immunosu

Torque Teno Virus Monitoring in Pediatric Hematopoietic Stem Cell Transplantation